‘ACOPP’ chemotherapy for older and less fit patients with Hodgkin lymphoma—A multicentre, retrospective study

Management of classical Hodgkin lymphoma in older patients is challenging due to poor tolerance of the chemotherapy regimens used in younger patients. We modified the BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone), whereby bleomycin and etoposide were removed and cyclophosphamide dose was reduced, for older patients with co‐morbidities. Here we present data from the first 41 patients treated with ‘ACOPP’ across 3 centres, demonstrating that it can be delivered, with a favourable toxicity profile (TRM 2%) and promising efficacy (2‐year PFS and OS, 73% (95% CI: 52–94) and 93% (95% CI: 80–100) respectively).

[1]  G. Collins,et al.  Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity , 2023, Frontiers in Oncology.

[2]  E. Laurenti,et al.  Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy , 2022, Blood.

[3]  P. Feugier,et al.  Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study , 2021, Blood.

[4]  R. Advani,et al.  Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. , 2021, Blood advances.

[5]  J. Connors,et al.  Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study , 2021, Haematologica.

[6]  B. Cheson,et al.  Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. , 2020, The Lancet. Haematology.

[7]  J. Radford,et al.  Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY) , 2020, British journal of haematology.

[8]  P. McKay,et al.  ACOPP Chemotherapy for Frontline Treatment of Older Patients with Hodgkin Lymphoma - a Pilot Study , 2019, Blood.

[9]  E. Jaffe,et al.  Diagnosis of Hodgkin lymphoma in the modern era , 2018, British journal of haematology.

[10]  B. Böll,et al.  The treatment of older Hodgkin lymphoma patients , 2018, British journal of haematology.

[11]  R. Advani,et al.  Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Greil,et al.  PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group , 2017, The Lancet.

[13]  R. Greil,et al.  Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. , 2016, Blood.

[14]  R. Greil,et al.  Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial , 2015, The Lancet.

[15]  R. McNally,et al.  Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. , 2012, Blood.

[16]  V. Diehl,et al.  Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). , 2010, Blood.

[17]  J. Delabie,et al.  Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma , 2007, Leukemia & lymphoma.

[18]  Charles Enke,et al.  Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M P Lawton,et al.  Validation of the Cumulative Illness Rating Scale in a Geriatric Residential Population , 1995, Journal of the American Geriatrics Society.

[20]  H. Eich,et al.  A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.